Is PAHC stock a Buy, Sell, or Hold?

Based on our analysis, PAHC is currently a HOLD with moderate confidence. 📊 HOLD: PAHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of PAHC stock?

Our analysis estimates the fair value range for PAHC to be between $37.94 and $40.59. The current price is $40.15.

What is the analyst price target for PAHC?

The average Wall Street analyst price target for PAHC is $43.00. This implies a potential upside of 7.8% from current levels.

PAHC Stock Analysis: Buy, Sell, or Hold?

PAHC - Phibro Animal Health Corporation Class A

PHARMACEUTICAL PREPARATIONS

$40.15

0.26 (0.65%) ▲

HOLD

MODERATE Confidence

Protect Your PAHC Gains

Last Updated: January 30, 2026

Earnings: Feb 04, 2026 4d

Get Alerted When PAHC Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: PAHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 10.2%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$64.58

Based on 7.1% avg growth

INTRINSIC VALUE TODAY

$40.10

Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.2x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: PAHC is currently trading at $40.15, which is considered slightly high relative to its 30-day fair value range of $37.94 to $40.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.2) compared to its historical average (15.2). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This pessimistic expectation contrasts with the company's recent 282.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, PAHC is showing sideways momentum. Immediate support is located at $38.29, while resistance sits at $42.82.

Market Sentiment: PAHC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position SLIGHTLY HIGH

Fair Price Range $37.94 - $40.59

Company Quality Score 55/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 50.0%

Protect Your Profits

Holding PAHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Options cheap (IV 0th percentile)
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($43.00)

Fair Price Analysis

30-Day Fair Range $37.94 - $40.59

Current vs Fair Value SLIGHTLY HIGH

Expected Move (7 Days) ±$2.78 (6.9%)

Support & Resistance Levels

Support Level $38.29

Resistance Level $42.82

Current Trend Sideways

Fundamental Context

Forward P/E (Next Year Est.) 13.22

Wall Street Target $43.00 (+7.8%)

Revenue Growth (YoY) 39.7%

Earnings Growth (YoY) 282.4%

Profit Margin 4.8%

Valuation Discount vs History -4.6% cheaper

PE vs Historical 13.2 vs 15.2 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -4.6% (market-implied from PE analysis)

1-Year Target $38.06 (-5%)

2-Year Target $36.30 (-9%)

3-Year Target $34.63 (-13%)

3-Yr Target (if PE normalizes) (PE: 13→15) $39.84 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.3, Growth: 10.2%) $90.05 (+126%)

Base: (SPY PE: 13.2, Growth: 10.2%) $53.37 (+34%)

Bear: (PE: 11.2, Growth: 10.2%) $45.36 (+14%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (13x PE) as earnings recover.

Trailing PE: 23.66 | Current EPS (TTM): $1.67

Bull Case $78.58 (+97%)

Analyst growth 80.7%, PE expands to 26.0

Base Case $71.43 (+79%)

Market implied 80.7%, PE stable at 23.7

Bear Case $26.87 (-33%)

Severe decline -20.0%, PE contracts to 20.1

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 13.2 to 15.2

Stabilization Target: $45.88 (+15.0%)

PE Expansion Potential: +15.0%

Last updated: January 30, 2026 5:38 PM ET
Data refreshes hourly during market hours. Next update: 6:38 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is PAHC showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Jack Bendheim SELL 3520 shares 2025-10-23

Jack Bendheim SELL 11859 shares 2025-10-22

Jack Bendheim SELL 16075 shares 2025-10-20

View Insider Activity Scanner

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
NBIX Neurocrine Biosciences I…	STRONG BUY 25 analysts	$179	62 BUY
ZTS Zoetis Inc	STRONG BUY 19 analysts	$158	56 HOLD
LNTH Lantheus Holdings Inc	STRONG BUY 13 analysts	$84	57 HOLD
BCRX BioCryst Pharmaceuticals…	STRONG BUY 12 analysts	$21	55 HOLD
HCM HUTCHMED DRC	STRONG BUY 14 analysts	$21	57 HOLD

NBIX Neurocrine Biosci…

62 BUY

ZTS Zoetis Inc

56 HOLD

LNTH Lantheus Holdings…

57 HOLD

BCRX BioCryst Pharmace…

55 HOLD

HCM HUTCHMED DRC

57 HOLD

Advanced PAHC Option Strategies

Professional options setups generated by AI based on today's PAHC price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for PAHC

PAHC Technical Chart PAHC Price Prediction PAHC Earnings Date PAHC Investment Advisor PAHC Fair Price Analyzer PAHC Options Advisor PAHC Options Chain PAHC Options Analysis PAHC Competitors

Compare PAHC with Other Stocks

Create New Comparison

Tradestie